First‐trimester pre‐eclampsia screening and adverse pregnancy outcomes beyond pre‐eclampsia
International Journal of Gynecology & Obstetrics · 2026
DOI: 10.1002/ijgo.70995 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Linus L T Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong. Hauptthemen laut MEDLINE: Pre-Eclampsia, Pregnancy Outcome, Premature Birth. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Objective
To determine if those screened as high‐risk for preterm pre‐eclampsia at first‐trimester Fetal Medicine Foundation (FMF)‐based screening and given aspirin are at higher risk of adverse pregnancy outcomes, even after adjusting for pre‐eclampsia.
Methods
This retrospective cohort study included 1623 ethnically Chinese women who received FMF‐based pre‐eclampsia screening, and subsequently delivered within our hospital system. Pregnancy outcomes were compared between screen‐positives (high risk, given aspirin) and screen‐negatives, and adjusted by pre‐eclampsia status and any hypertension in pregnancy.
Results
After adjustment for pre‐eclampsia, screen‐positives still delivered earlier (−0.7 weeks, P < 0.001), with a higher rate of preterm birth (PTB) before 37 weeks (odds ratio [OR] 2.413, P = 0.002). Birth weight centiles in the screen‐positive group were lower (−8.3, P = 0.001), with small‐for‐gestational‐age (SGA) being more common in the screen‐positive group (OR 2.697, P < 0.001). Emergency cesarean was more common (OR 2.943, P < 0.001), rate of admission to neonatal intensive care unit was higher (OR 2.044, P = 0.014), and stillbirths were more common (OR 5.131, P = 0.038).
Conclusion
The risks for SGA/fetal growth restriction and PTB were significantly higher in those who screened positive at FMF first‐trimester pre‐eclampsia screening, even after adjusting for pre‐eclampsia, and they may benefit from increased surveillance. Components of FMF‐based first‐trimester pre‐eclampsia screening overlap substantially with uteroplacental great obstetrical syndromes, and help to identify a broader placental‐risk phenotype. Future research may explore how this information could be further operationalized—through refinement of risk thresholds and incorporation of adjunctive strategies. Nevertheless, the lack of highly effective strategies to further stratify and prevent SGA/fetal growth restriction and spontaneous PTB remains a challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong.
ORCID-Profile: Linus L T Lee, Lin Wai Chan
Zitieren
APA
Lee, L. L. T., Ho, S. Y., & Chan, L. W. (2026). First‐trimester pre‐eclampsia screening and adverse pregnancy outcomes beyond pre‐eclampsia. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.70995
Vancouver
Lee LLT, Ho SY, Chan LW. First‐trimester pre‐eclampsia screening and adverse pregnancy outcomes beyond pre‐eclampsia. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.70995
BibTeX
@article{Lee2026,
author = {Lee, Linus L T and Ho, Suet Yin and Chan, Lin Wai},
title = {First‐trimester pre‐eclampsia screening and adverse pregnancy outcomes beyond pre‐eclampsia},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
doi = {10.1002/ijgo.70995}
}
EUVIMED